Group 1: Domestic News - Xi Jinping emphasized the responsibilities of central enterprises to better serve the national agenda and contribute to high-quality economic development, urging them to focus on core functions and enhance competitiveness [2] - Premier Li Qiang highlighted the importance of central enterprises in advancing new infrastructure construction and ensuring the self-sufficiency of industrial and supply chains, while also calling for deeper reforms in state-owned enterprises [3] - The National Housing and Urban-Rural Development Conference acknowledged the significant changes in the real estate market and emphasized the potential for further development, advocating for a new model of real estate development that meets public housing needs [4] Group 2: International News - The U.S. GDP for Q3 grew by 4.3%, exceeding expectations of 3.3%, with consumer spending showing strong growth at 3.5%, indicating robust economic expansion despite rising borrowing costs [5] - U.S. durable goods orders fell by 2.2% in October, significantly below the expected decline of 1.5%, although year-on-year growth remained at 4.7%, indicating resilience in manufacturing orders [6] Group 3: Bond Market Dynamics - The bond market showed signs of strength with a notable entry of configuration funds, leading to a decline in yields for 10-year government bonds to 1.8350% and 10-year policy bank bonds to 1.898% [11] - The convertible bond market experienced adjustments, with major indices declining and a majority of individual bonds falling, indicating a mixed performance in the market [17] Group 4: Commodity Market - International crude oil prices continued to rise, with WTI crude up by approximately 0.64% to $58.38 per barrel, and natural gas prices surged over 10% [7] Group 5: Financial Market Operations - The central bank conducted a reverse repurchase operation of 593 billion yuan at a fixed rate of 1.40%, resulting in a net withdrawal of 760 billion yuan due to maturing reverse repos [8] - The funding rates remained low, with DR001 and DR007 declining to 1.269% and 1.411% respectively, indicating a continued loose monetary environment [9]

Policy Developments - The National Healthcare Security Administration is soliciting public opinions on the "Traditional Chinese Medicine Decoction Pieces Traceability Code Encoding Rules" to promote a unified traceability system for traditional Chinese medicine [1] - The National Medical Products Administration has released the "Internet Drug and Medical Device Information Service Filing Management Regulations," which will take effect immediately [2] Drug and Device Approvals - YHLO Biotech announced that it has received medical device registration certificates for two products from the Guangdong and Hunan Provincial Medical Products Administration [3] - Lianhuan Pharmaceutical reported that its raw material drug, Levonorgestrel, has passed pre-certification by the World Health Organization, although this will not significantly impact current operating performance [4] Capital Market Activities - Taiji Group plans to publicly transfer 40% of its stake in the subsidiary company Aida through a public listing, with an initial transfer price of 108,000 yuan [5] - Jiangsu Zhiyuan Pharmaceutical has completed nearly 300 million yuan in Pre-IPO financing, led by Innovation Works [6] Industry Developments - Tongxin Medical announced that its fully magnetic levitation artificial heart has completed enrollment of 100 patients in the INNOVATE clinical trial in the U.S. [7][8] - Novo Nordisk plans to launch the oral version of Wegovy in the U.S. in January 2026, marking it as the first oral GLP-1 drug for weight management [9] Public Sentiment - The Zhejiang Provincial Government has dispatched a working group to oversee the follow-up handling of a medical incident involving a child's postoperative death at Ningbo University Women's and Children's Hospital [10] Regulatory Actions - Haohai Biological Technology announced that its controlling shareholder, Jiang Wei, has been fined 14.63 million yuan by the China Securities Regulatory Commission for insider trading, which will not affect the company's daily operations [11]

Core Viewpoint - The announcement highlights that the administrative penalty imposed on Jiang Wei, a controlling shareholder and actual controller of Shanghai Haohai Biological Technology Co., Ltd., is related to personal insider trading activities and does not impact the company's operations or finances significantly [1][2]. Group 1: Administrative Penalty Details - Jiang Wei received an administrative penalty from the China Securities Regulatory Commission (CSRC) for insider trading and advising others to trade securities, resulting in a total penalty of 19.34 million yuan, which includes the confiscation of illegal gains of 4.71 million yuan and a fine of 14.63 million yuan [1][3]. - The penalty is solely related to Jiang Wei's personal actions and is not connected to the company's business operations [2]. Group 2: Company Operations and Management - The company confirmed that Jiang Wei does not participate in daily management, and the penalty will not have a significant impact on the company's daily operations, business, or financial status [2]. - As of the announcement date, all production and operational activities of the company are proceeding normally and in an orderly manner [2]. Group 3: Shareholding and Wealth Information - Jiang Wei and his spouse, You Jie, are the controlling shareholders of the company, holding 28.53% and 17.29% of shares, respectively [3]. - According to the 2025 Hurun Global Rich List, the couple's wealth is estimated at 7.3 billion yuan, ranking them 3206th [3]. Group 4: Company Profile - Shanghai Haohai Biological Technology Co., Ltd. is a technology innovation company specializing in the research, production, and sales of medical devices and pharmaceuticals using biomedical materials and genetic engineering technology [3]. - The company is recognized as one of the leading hyaluronic acid producers in China, with a business matrix covering four main categories: hyaluronic acid, epidermal repair gene engineering preparations, and radiofrequency and laser equipment [3].

Market Performance - The US stock market closed higher, with the S&P 500 index reaching a new high. The Dow Jones increased by 0.16%, the S&P 500 rose by 0.46%, and the Nasdaq gained 0.57% [1] - Major tech stocks performed well, with Nvidia up 3.01%, Broadcom up 2.30%, Amazon up 1.62%, and Google A shares up 1.48% [1] Commodity Prices - Spot silver continued its strong performance, reaching a new historical high, increasing by 3% to $71.06 per ounce, with a year-to-date increase of 145% [2] - Spot gold rose by 0.8%, reaching $4478.52 per ounce, hitting a record high during the trading session [3] - International oil prices slightly increased, with New York crude oil futures closing at $58.38 per barrel [4] Regulatory Developments - The National Development and Reform Commission, Ministry of Education, and Ministry of Finance in China issued a notice to improve kindergarten fee policies, emphasizing the need for financial transparency and regulation of fees [4] - A new regulation on food safety in live-streaming e-commerce is set to be published, outlining responsibilities for platform operators and marketing personnel [5][6] Corporate News - Sunac China announced that approximately $9.6 billion of its existing offshore debt has been fully released and exempted [6] - Haibo Technology plans to invest 2 billion yuan to build a smart green energy storage factory [6] - Bethel plans to issue H-shares and list on the Hong Kong Stock Exchange [6] - Ningbo Port intends to acquire 100% equity of Zhoushan Port Comprehensive Bonded Zone for 706 million yuan [6]

Macro News - Xi Jinping emphasized the importance of central enterprises in supporting national strategies and enhancing core competitiveness, urging them to focus on their main responsibilities and optimize the layout of state-owned economy [4] - The meeting of central enterprise leaders highlighted the need for strong support in major infrastructure construction and the promotion of new infrastructure development [4] Industry News - Shenzhen banks have raised the minimum interest rate for business loans secured by real estate to 2.35% annually, up from a previous low of 2.2% [8] - The first batch of L3-level highway autonomous vehicle special license plates has been issued in Beijing, allowing conditional autonomous driving on specific highways [9] - The sixth round of national high-value medical consumables procurement has started, introducing a price anchor concept to balance price reductions and prevent malicious underpricing [9] Company News - SMIC has implemented a price increase of approximately 10% on certain production capacities [10] - Oriental Yuhong reported that its wholly-owned subsidiary in the U.S. was allegedly a victim of telecom fraud, with an involved amount of approximately 12.118 million yuan [10] - Aiko Cyber announced it won the bid for the BEST and HL-3 nuclear fusion power project [11] - Zhenyu Technology plans to raise no more than 1.88 billion yuan for lithium battery precision structural component expansion projects [11] Global Market - U.S. stock indices collectively rose, with the S&P 500 index reaching a new closing high [12] - International gold and silver prices hit historical highs, with COMEX gold futures rising by 1.02% to $4,515 per ounce and silver futures up by 4.44% to $71.61 per ounce [14]

证券代码：688366 证券简称：昊海生科公告编号：2025-052 上海昊海生物科技股份有限公司 关于公司控股股东、实际控制人之一因非本公司事项 收到《行政处罚决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、基本情况 上海昊海生物科技股份有限公司（以下简称"公司"）控股股东、实际控制人之一蒋伟先生此前因非本公 司事项，收到中国证券监督管理委员会（以下简称"中国证监会"）出具的《行政处罚事先告知书》（处 罚字[2025]67号）。具体内容详见公司2025年9月17日于上海证券交易所网站（www.sse.com.cn）披露的 《上海昊海生物科技股份有限公司关于公司控股股东、实际控制人之一因非本公司事项收到〈行政处罚 事先告知书〉的公告》（公告编号：2025-042）。 近日，公司收到蒋伟先生告知，获悉其因前述事项，收到了中国证监会出具的《行政处罚决定书》 （[2025]151号）。行政处罚决定书的主要内容为：因蒋伟先生内幕交易、建议他人买卖证券行为，中 国证监会决定没收其违法所得4,709,741.41元 ...

Core Viewpoint - The announcement from Haohai Biological Technology indicates that the company's actual controller, Jiang Wei, has been penalized for insider trading, with a total fine and confiscation amounting to 19.34 million yuan. The company asserts that this matter is unrelated to its operations and will not significantly impact its business or financials [2][3]. Group 1: Regulatory Actions - Jiang Wei received an administrative penalty from the China Securities Regulatory Commission (CSRC) for insider trading, with a confiscation of illegal gains amounting to 4.71 million yuan and a fine of 14.63 million yuan, totaling 19.34 million yuan [2][3]. - The penalty is directed at Jiang Wei personally, and the company emphasizes that it is not involved in the matter, as Jiang does not participate in daily management [2][3]. Group 2: Company Background - Haohai Biological Technology was established in 2007 and listed on the Hong Kong Stock Exchange in 2015, later becoming the first company to be listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board in October 2019 [2][3]. - The company primarily engages in the production and sales of biopharmaceuticals, including medical sodium hyaluronate gel, epidermal growth factor, chitosan, collagen, artificial crystals, and ophthalmic implants [3]. Group 3: Financial Performance - For the first three quarters of 2025, Haohai Biological Technology reported total revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down over 10% [4]. - The net cash flow from operating activities for the same period was 377 million yuan, reflecting a decline of 12.45% year-on-year, attributed to insufficient domestic consumer demand, price competition, and tax rate adjustments [4]. Group 4: Capital Operations - Despite the investigation of its actual controller, Haohai Biological Technology continued its capital operations, announcing on November 9 that it plans to acquire the remaining 20% stake in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for 74 million yuan, which would result in the company holding 100% of the target company's equity [5].

Mergers and Acquisitions - Jinke Environment plans to acquire 100% equity of Tangshan Eric Environmental Technology Co., Ltd. for a total consideration of 84.8 million yuan, which includes 54.8 million yuan in cash and a 30 million yuan value of new water island products. This transaction does not constitute a related party transaction or a major asset restructuring [1] - Ningbo Port intends to acquire 100% equity of Zhoushan Comprehensive Bonded Zone Terminal Co., Ltd. from its controlling shareholder, Ningbo Zhoushan Port Group Co., Ltd., for a cash consideration of 706 million yuan. This transaction is classified as a related party transaction but does not constitute a major asset restructuring [2] - ST Jinglan plans to acquire 51% equity of South Africa's NORTHWEST VANADIUM PROPRIETARY LIMITED for 1 million USD, which primarily holds exploration rights for exclusive vanadium-titanium magnetite mineral resources [3] Shareholding Changes - Oke Yi's shareholder Yuan Meihe plans to reduce his holdings by no more than 1.89% of the company's total shares, which amounts to a maximum of 3 million shares [4] - Unisplendour's shareholder, holding 5.5% (157 million shares), plans to reduce holdings by no more than 1% of the total shares, equating to a maximum of 28.6 million shares [5] - Huaxin Cement's shareholder, holding over 5%, plans to increase its stake in the company by no less than 200 million yuan and no more than 400 million yuan, funded by its own resources and a special loan of up to 360 million yuan from ICBC Hubei Branch [6] Risk Matters - Oriental Yuhong reported that its wholly-owned subsidiary in the U.S., OYH Construction Materials LLC, is suspected to have fallen victim to a telecom scam involving approximately 1.7183 million USD (about 12.118 million yuan). The company has reported the incident to local authorities and established a special task force for investigation and risk management [7] - Haohai Biological's controlling shareholder, Jiang Wei, was fined 14.6292 million yuan by the China Securities Regulatory Commission for insider trading and advising others on securities trading. This penalty is unrelated to the company's operations and will not significantly impact its daily business or finances [8]

Shareholder Reductions - Zhang Fan from 壹网壹创 plans to reduce his holdings by no more than 2.5% [1] - Yan Jun, honorary chairman and chief scientist of 航宇微, intends to reduce his holdings by no more than 1.66% [1] - 长安信托·中保投1号信托, a shareholder of 紫光股份, plans to reduce its holdings by no more than 1% [1] - Jiang Shuguang, deputy general manager of 崇达技术, plans to reduce his holdings by no more than 200,000 shares [1] - 热景生物 intends to sell back repurchased shares not exceeding 1.8542 million shares [1] - Yuan Meihe, a shareholder of 欧科亿, plans to reduce his holdings by no more than 1.89% [1] - Zhu Fengxue and his concerted actions from 中曼石油 will collectively reduce their holdings by 0.35% [1] - Tokyo Guorui, a shareholder of 燕东微, has already reduced its holdings by 0.88% [1] - Huaguang New Materials' shareholder, Huan Guang Investment, has cumulatively reduced its holdings by 1.60% [1] - Jiayuan Group has reduced its holdings in 吉祥航空 by 8.6065 million shares [1] - Longgao Electric New from 富特科技 has cumulatively reduced its holdings by 1.00% [1] - Actual controller Shi Huiqing from 可川科技 has reduced his holdings by 1.05% [1] - Lu Xinchun, a shareholder of 华海清科, has reduced his holdings by 3.3156 million shares [1] Other Corporate Actions - 建设机械 has terminated the issuance of shares to specific objects [1] - 蒋伟, the controlling shareholder of 吴海生科, has been fined 14.6292 million yuan by the China Securities Regulatory Commission [1]

Group 1 - The actual controller of Haohai Biological Technology, Jiang Wei, was penalized approximately 19.34 million yuan for insider trading and suggesting others to trade securities, with 4.71 million yuan confiscated as illegal gains and a fine of 14.63 million yuan imposed by the China Securities Regulatory Commission [2][4]. - Haohai Biological Technology stated that the penalty is directed at Jiang Wei personally and is unrelated to the company, asserting that it will not significantly impact the company's daily operations, business, or finances [4][5]. - As of the end of the third quarter, Jiang Wei is the largest shareholder of Haohai Biological Technology, holding 66.528 million shares, which accounts for 28.6% of the total shares [4][5]. Group 2 - Haohai Biological Technology plans to enter the biological amniotic membrane sector by acquiring a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan [7]. - Ruiji Biological specializes in the research, production, and sales of biological amniotic membranes, which are used in orthopedic and ophthalmic fields [7]. - The investment aims to enhance Haohai's product portfolio and expand its business coverage in the ophthalmic and orthopedic sectors [7]. Group 3 - Ruiji Biological's financial performance is concerning, with a projected net profit of -12.74 million yuan for 2024 and a loss of 11.93 million yuan for the first three quarters of 2025 [8][9]. - The transaction does not include performance commitments or profit guarantees, indicating potential risks for Haohai if Ruiji's performance declines [9]. - As of December 23, Haohai Biological Technology's stock price was 44.25 yuan per share, with a total market capitalization of 10.292 billion yuan [10].